# US 2024/0189452 A1 · Recombinant Adeno-Associated Virus Encoding Methyl-CPG Binding Protein 2 for Treating PITT Hopkins Syndrome VIA Intrathecal Delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189452 A1
- Document ID: US20240189452A1
- Status: Published application
- Kind: A1
- Application number: 18/286,626
- Filed: 2022-04-13
- Published: 2024-06-13
- Earliest claimed: 2021-04-13
- Assignees: Research Institute At Nationwide Children's Hospital
- Applicants: Research Institute At Nationwide Children's Hospital
- Inventors: Kathrin Christine Meyer; Cassandra Nicole Dennys-Rivers
- Web page: https://patentgrep.com/patent/US20240189452A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 38/1709: {from mammals}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61P 25/00: Drugs for disorders of the nervous system
- C07K 14/4702: {Regulators; Modulating activity}
- C12N 15/86: Viral vectors
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

Methods and materials for treating Pitt Hopkins Syndrome comprising intrathecal delivery of recombinant Adeno-associated virus 9 (rAAV9) encoding Methyl-CpG binding protein 2 (MECP2) are provided.

## Claims

### Claim 1

A method of treating Pitt Hopkins Syndrome comprising administering a recombinant adeno-associated virus (rAAV9) encoding Methyl-CpG binding protein 2 (MECP2) to a subject in need thereof.

### Claim 2

A method of increasing Methyl-CpG binding protein 2 (MECP2) levels in a subject suffering from Pitt Hopkins Syndrome comprising administering a recombinant adeno-associated virus (rAAV9) or a rAAV viral particle encoding MECP2 to the subject.

### Claim 3

A method of delivering a polynucleotide sequence encoding the Methyl-CpG binding protein 2 (MECP2) to a subject suffering from PTHS comprising administering a recombinant adeno-associated virus (rAAV9) or a rAAV viral particle encoding MECP2 to the subject.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3 wherein the rAAV comprises the nucleotide sequence of SEQ ID NO: 3.

### Claim 5 (depends on 4)

The method of claim 4 wherein the rAAV further comprises the promoter sequence of SEQ ID NO: 2.

### Claim 6 (depends on 4, 5)

The method of any one of claim 4 or 5 wherein the rAAV further comprises an SV40 intron and a synthetic polyadenylation signal sequence.

### Claim 7 (depends on 4, 5, 6)

The method of any one of claims 4-6 wherein the rAAV further comprises an inverted terminal repeat (ITR).

### Claim 8 (depends on 7)

The method of claim 7 wherein the rAAV comprises a mutant ITR and a wild type ITR.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8 wherein the rAAV comprises the nucleotide sequence of SEQ ID NO: 5.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claim 1-9, wherein the rAAV is administered using direct injection into the cerebrospinal fluid, intracerebroventricular delivery, intrathecal delivery or intravenous delivery

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10 wherein the patient has a mutation in the TCF4 gene.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11 wherein the patient is suffering from one or more of symptoms, wherein the symptom is intellectual disability, developmental delay, breathing problems, recurrent seizures (epilepsy), and distinctive facial features, delayed or lack of speech, impaired communication skills , impaired socialization skills, hyperventilation, apnea, cyanosis, clubbing of fingers and/or toes, thin eyebrows, sunken eyes, a prominent nose with a high nasal bridge, a pronounced double curve of the upper lip (cupid's bow), a wide mouth with full lips, widely spaced teeth, thick and/or cup-shaped ears, constipation, gastrointestinal problems, microcephaly, myopia, strabismus, short stature, minor brain abnormalities, small hands and/or feet, single crease across the palm of the hands, pes planus, fleshy pads at the tips of the fingers/or toes, cryptorchidism, stereotypic movements, involuntary hand movements, loss of gait, loss of muscle tone, scoliosis, sleep disturbances, coordination or balance problems, anxiety, behavioral problems, bruxism, excessive saliva and drooling, cardiac problems, arrhythmia, feeding problems or swallowing problems.

### Claim 13

A composition for treating Pitt Hopkins Syndrome wherein the composition comprises a recombinant adeno-associated virus (rAAV9) encoding Methyl-CpG binding protein 2 (MECP2).

### Claim 14

A composition for increasing Methyl-CpG binding protein 2 (MECP2) levels in a subject suffering from Pitt Hopkins Syndrome wherein the composition comprises a recombinant adeno-associated virus (rAAV9) or a rAAV viral particle encoding MECP2 to the subject.

### Claim 15

A composition for delivering a polynucleotide sequence encoding the Methyl-CpG binding protein 2 (MECP2) to a subject suffering from PTHS wherein the composition comprises a recombinant adeno-associated virus (rAAV9) or a rAAV viral particle encoding MECP2 to the subject.

### Claim 16 (depends on 13, 14, 15)

The composition of any one of claims 13-15, wherein the rAAV comprises the nucleotide sequence of SEQ ID NO: 3.

### Claim 17 (depends on 16)

The composition of claim 16 wherein the rAAV further comprises the promoter sequence of SEQ ID NO: 2.

### Claim 18 (depends on 16, 17)

The composition of claim 16 or 17 wherein the rAAV further comprises an SV40 intron and a synthetic polyadenylation signal sequence.

### Claim 19 (depends on 16, 17, 18)

The composition of any one of claims 16-18 wherein the rAAV further comprises an inverted terminal repeat (ITR).

### Claim 20 (depends on 19)

The composition of claim 19 wherein the rAAV comprises a mutant ITR and a wild type ITR.

### Claim 21 (depends on 13, 14, 15, 16, 17, 18, 19, 20)

The composition of any one of claims 13-20 wherein the rAAV comprises the nucleotide sequence of SEQ ID NO: 5.

### Claim 22 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21)

The composition of any one of claim 13-21, wherein the composition is formulated for direct injection into the cerebrospinal fluid, intracerebroventricular delivery, intrathecal delivery or intravenous delivery.

### Claim 23 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The composition of any one of claims 13-22 wherein the patient has a mutation in the TCF4 gene.

### Claim 24 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The composition of any one of claims 13-23 wherein the patient is suffering from one or more of symptoms, wherein the symptom is intellectual disability, developmental delay, breathing problems, recurrent seizures (epilepsy), and distinctive facial features, delayed or lack of speech, impaired communication skills , impaired socialization skills, hyperventilation, apnea, cyanosis, clubbing of fingers and/or toes, thin eyebrows, sunken eyes, a prominent nose with a high nasal bridge, a pronounced double curve of the upper lip (cupid's bow), a wide mouth with full lips, widely spaced teeth, thick and/or cup-shaped ears, constipation, gastrointestinal problems, microcephaly, myopia, strabismus, short stature, minor brain abnormalities, small hands and/or feet, single crease across the palm of the hands, pes planus, fleshy pads at the tips of the fingers/or toes, cryptorchidism, stereotypic movements, involuntary hand movements, loss of gait, loss of muscle tone, scoliosis, sleep disturbances, coordination or balance problems, anxiety, behavioral problems, bruxism, excessive saliva and drooling, cardiac problems, arrhythmia, feeding problems or swallowing problems.

### Claim 25

Use of a recombinant adeno-associated virus (rAAV9) encoding Methyl-CpG binding protein 2 (MECP2) for the preparation of a medicament for treating Pitt Hopkins Syndrome (PTHS) in a patient in need thereof.

### Claim 26

Use of a recombinant adeno-associated virus (rAAV9) encoding Methyl-CpG binding protein 2 (MECP2) for the preparation of a medicament for increasing Methyl-CpG binding protein 2 (MECP2) levels in a subject suffering from Pitt Hopkins Syndrome

### Claim 27

Use of a recombinant adeno-associated virus (rAAV9) encoding Methyl-CpG binding protein 2 (MECP2) for the preparation of a medicament for delivering a polynucleotide sequence encoding the Methyl-CpG binding protein 2 (MECP2) to a subject suffering from PTHS.

### Claim 28 (depends on 25, 26, 27)

The use of any one of claims 25-27 wherein the rAAV comprises the nucleotide sequence of SEQ ID NO: 3.

### Claim 29 (depends on 28)

The use of claim 28 wherein the rAAV further comprises the promoter sequence of SEQ ID NO: 2.

### Claim 30 (depends on 28, 29)

The use of any one of claim 28 or 29 wherein the rAAV further comprises an SV40 intron and a synthetic polyadenylation signal sequence.

### Claim 31 (depends on 28, 29, 30)

The use of any one of claims 28-30 wherein the rAAV further comprises an inverted terminal repeat (ITR).

### Claim 32 (depends on 31)

The use of claim 31 wherein the rAAV comprises a mutant ITR and a wild type ITR.

### Claim 33 (depends on 25, 26, 27, 28, 29, 30, 31, 32)

The use of any one of claims 25-32 wherein the rAAV comprises the nucleotide sequence of SEQ ID NO: 5.

### Claim 34 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33)

The use of any one of claim 25-33, wherein the medicament is formulated to be administered using direct injection into the cerebrospinal fluid, intracerebroventricular delivery, intrathecal delivery or intravenous delivery.

### Claim 35 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 25-34 wherein the patient has a mutation in the TCF4 gene.

### Claim 36 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 25-35 wherein the patient is suffering from one or more of symptoms, wherein the symptom is intellectual disability, developmental delay, breathing problems, recurrent seizures (epilepsy), and distinctive facial features, delayed or lack of speech, impaired communication skills , impaired socialization skills, hyperventilation, apnea, cyanosis, clubbing of fingers and/or toes, thin eyebrows, sunken eyes, a prominent nose with a high nasal bridge, a pronounced double curve of the upper lip (cupid's bow), a wide mouth with full lips, widely spaced teeth, thick and/or cup-shaped ears, constipation, gastrointestinal problems, microcephaly, myopia, strabismus, short stature, minor brain abnormalities, small hands and/or feet, single crease across the palm of the hands, pes planus, fleshy pads at the tips of the fingers/or toes, cryptorchidism, stereotypic movements, involuntary hand movements, loss of gait, loss of muscle tone, scoliosis, sleep disturbances, coordination or balance problems, anxiety, behavioral problems, bruxism, excessive saliva and drooling, cardiac problems, arrhythmia, feeding problems or swallowing problems.
